公开(公告)号：US10725057B2

公开(公告)日：2020-07-28

申请号：US15312777

申请日：2015-05-21

Applicant: Shiseido Company, Ltd

Inventor： Yosuke Tojo ,  Masashi Mita ,  Wolfgang Lindner

IPC: G01N33/00 ,  G01N33/94 ,  G01N30/06 ,  G01N33/48 ,  G01N30/88 ,  B01D15/12 ,  B01D15/16 ,  B01D15/26 ,  B01D15/38

Abstract: The present invention addresses the problem of providing a novel method for the pretreatment of a biological sample containing lenalidomide enantiomer and thereby establishing a simple and accurate method for the quantitative analysis of lenalidomide enantiomer. In the present invention, the racemization and decomposition of lenalidomide enantiomer in a biological sample can be prevented by the deproteinization under acidic conditions of the biological sample containing lenalidomide enantiomer, and the lenalidomide enantiomer can be simply and accurately quantitatively analyzed by subjecting to HPLC the biological sample that has been pretreated in such a way.

公开(公告)号：US20170190686A1

公开(公告)日：2017-07-06

申请号：US15312788

申请日：2015-05-21

Applicant: Shiseido Company, Ltd

Inventor： Yosuke Tojo ,  Masashi MITA ,  Wolfgang Lindner

IPC: C07D401/04

CPC classification number: C07D401/04 ,  A61K31/454 ,  B01D15/3833 ,  B01D15/426 ,  G01N30/88

Abstract: The problem addressed by the present invention is to provide a novel method for separating and purifying pure enantiomer of lenalidomide. Pure enantiomer of lenalidomide can be separated and purified by using, as the mobile phase, an organic solvent selected from the group consisting of aprotic solvents, secondary alcohols, and mixtures thereof.

公开(公告)号：US10907208B2

公开(公告)日：2021-02-02

申请号：US16412993

申请日：2019-05-15

Applicant: Shiseido Company, Ltd

Inventor： Yosuke Tojo ,  Masato Iino ,  Chieko Mizumoto ,  Yuzo Yoshida ,  Yuko Matsuura ,  Hisashi Mori

IPC: C12N9/90 ,  C12Q1/6876 ,  G01N33/50 ,  A61K38/01 ,  A61K36/9068 ,  A61K36/28 ,  G01N33/68 ,  C12Q1/6883 ,  A61K36/899 ,  A61K8/9789 ,  A61K8/9794 ,  A61K8/64 ,  A61Q19/00

Abstract: The purpose of the present invention is to develop a method for screening drugs having the effect of increasing skin barrier function in in vitro studies and to evaluate barrier function in the skin. Candidate drugs can be screened by using the activity and/or expression level of serine racemase as an indicator.

公开(公告)号：US10047068B2

公开(公告)日：2018-08-14

申请号：US15312788

申请日：2015-05-21

Applicant: Shiseido Company, Ltd

Inventor： Yosuke Tojo ,  Masashi Mita ,  Wolfgang Lindner

IPC: C07D401/04

Abstract: The problem addressed by the present invention is to provide a novel method for separating and purifying pure enantiomer of lenalidomide. Pure enantiomer of lenalidomide can be separated and purified by using, as the mobile phase, an organic solvent selected from the group consisting of aprotic solvents, secondary alcohols, and mixtures thereof.

公开(公告)号：US20160069867A1

公开(公告)日：2016-03-10

申请号：US14477213

申请日：2014-09-04

Applicant: SHISEIDO COMPANY, LTD.

Inventor： Yosuke Tojo ,  Masato lino ,  Chieko Mizumoto ,  Yuzo Yoshida ,  Hisashi Mori

IPC: G01N33/50 ,  A61K36/28 ,  A61K36/9068 ,  C12Q1/68 ,  A61K38/01

CPC classification number: C12Q1/6876 ,  A61K8/645 ,  A61K8/97 ,  A61K36/28 ,  A61K36/899 ,  A61K36/9068 ,  A61K38/011 ,  A61K2800/782 ,  A61Q19/00 ,  C12Q1/6883 ,  C12Q2600/136 ,  C12Q2600/148 ,  C12Q2600/158 ,  G01N33/5044 ,  G01N33/6812 ,  G01N2333/968 ,  G01N2333/99 ,  G01N2800/20 ,  A61K2300/00

Abstract: The object of the invention is to develop a screening method for drugs having effects of increasing skin barrier function in in vitro experimentation, and to evaluate skin barrier function for skin. Serine racemase activity and/or expression level are used as an indicator to allow screening of candidate drugs.

Abstract translation: 本发明的目的是开发一种在体外实验中具有增加皮肤屏障功能作用的药物的筛选方法，并评估皮肤的皮肤屏障功能。 使用丝氨酸消旋酶活性和/或表达水平作为候选药物筛选的指标。

公开(公告)号：US10337064B2

公开(公告)日：2019-07-02

申请号：US15123274

申请日：2015-03-05

Applicant: Shiseido Company, Ltd

Inventor： Yosuke Tojo ,  Masato Iino ,  Chieko Mizumoto ,  Yuzo Yoshida ,  Yuko Matsuura ,  Hisashi Mori

IPC: A61K8/64 ,  C12N9/90 ,  C12Q1/6876 ,  G01N33/50 ,  A61K38/01 ,  A61K36/9068 ,  A61K36/28 ,  G01N33/68 ,  C12Q1/6883 ,  A61K36/899 ,  A61K8/97 ,  A61Q19/00

Abstract: The purpose of the present invention is to develop a method for screening drugs having the effect of increasing skin barrier function in in vitro studies and to evaluate barrier function in the skin. Candidate drugs can be screened by using the activity and/or expression level of serine racemase as an indicator.